Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares traded down 6.1% on Thursday . The company traded as low as $78.14 and last traded at $79.55. 898,539 shares were traded during trading, a decline of 47% from the average session volume of 1,702,431 shares. The stock had previously closed at $84.68. Analyst Upgrades and Downgrades […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $88.51 and last traded at $88.27, with a volume of 1040253 shares traded. The stock had previously closed at $86.25. Analyst Ratings Changes A number of research analysts have […]
HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) in a report released on Thursday, Benzinga reports. They currently have a $87.00 price objective on the stock. Several other brokerages also recently commented on APLS. Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $90.00 to $105.00 […]
Should You Buy or Sell Apellis Pharmaceuticals Stock? Get The Latest APLS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.